Health care providers and patients should not use compounded products marketed as sterile by Greenpark Compounding Pharmacy due to a lack of sterility assurance, the Food and Drug Administration announced today. FDA recently recommended the compounder expand its recall of a compounded ophthalmic drug to include all unexpired compounded drugs intended to be sterile and stop their production until it implements adequate corrective actions. However, the company has refused to recall the products or cease compounding sterile drugs, FDA said. 

Related News Articles

Headline
The Food and Drug Administration is evaluating Chinese-made plastic syringes used to inject or withdraw fluids from the body, citing concern that they may…
Headline
Draeger Medical, Inc. is recalling its Carina Ventilators due to the presence of contaminants in the device’s airpath, which exceed acceptable levels if…
Headline
Crews are working to restore power and assess damage to a Pfizer plant in North Carolina that makes sterile injectables for U.S. hospitals after a tornado…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
The Consumer Financial Protection Bureau, Centers for Medicare & Medicaid Services, Department of Health and Human Services, and Department of the Treasury…
Headline
As urged by the AHA and its professional membership group the Association for Health Care Resource & Materials Management, the Food and Drug Administration…